Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonaprument in Dry Age-Related Macular Degeneration With Geographic Atrophy
NCT06510816Phase 3Active, not recruiting
- Sponsor
- Annexon Biosciences
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Antibody Fragments
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of vonaprument in age-related macular degeneration (AMD) (2 arms), sponsored by Annexon Biosciences. Primary endpoint: Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) >=15-letter Loss at 15 months. Started Jul 2024; status: active, not recruiting.
02
Drugs
vonaprument
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT06510816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06510816.